Cross-Sector entity
Of the tracked stories, 2 of 3 also mention Arcturus Therapeutics, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 176-day span. The busiest single day carried 2. The clearest coverage concentration is pharma: 2 of 3 stories, with the rest divided among 1 other category.
3 verified stories tracked
Last mentioned: 21h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention Arcturus Therapeutics, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 176-day span. The busiest single day carried 2. The clearest coverage concentration is pharma: 2 of 3 stories, with the rest divided among 1 other category. This profile follows 3 Cross-Sector stories mentioning Meiji Seika Pharma across the period from March 2, 2026 to August 24, 2026. The tracked stories average 2 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Meiji Seika Pharma. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
Meiji Seika Pharma will transfer manufacturing technology for its Japanese encephalitis vaccine, developed and marketed by KM Biologics in Japan, to Serum Institute of India. SII engineers have already visited Japan, and the Indian firm expects to file for regulatory approval as early as 2027.
Source: news.webindia123.com · aninews.in
Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Source: Seeking Alpha · Seeking Alpha
